Do Kyung Ryuk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Do Kyung Ryuk has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Nicolas A. Menzies
Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston MA, USA
7 shared publications Mauro Sanchez
Núcleo de Medicina Tropical, University of Brasília , Brasília
4 shared publications- Hening Cui
Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston MA, USA
3 shared publications - Katherine Chisholm Horton
Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
3 shared publications Kleydson Alves
Pan-American Health Organization, PAHO Brazil, Brasília, Brazil
3 shared publicationsLuiza Ohana Harada
Health and Environment Surveillance Secretariat, Ministry of Health , Brasilia
3 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
The Impact of Directly Observed Therapy on Successful Tuberculosis Treatment: A Statistical Analysis of National Notifications Data
Background: Directly Observed Therapy (DOT) is a recommended modality for tuberculosis (TB) treatment, yet is underutilized in many settings. Although DOT has been evaluated in clinical trials, less is known about its effectiveness in routine programs. We estimated the contribution of DOT to TB treatment success in Brazil. Methods: Using data from Brazil's National Disease Notification System for 2015–2018, we fit regression models estimating the relationship between DOT coverage and individual treatment success, leveraging municipality-level variation in DOT usage to avoid confounding due to nonrandom DOT receipt at the individual level. Models were adjusted for demographic and clinical covariates, using generalized estimating equations to account for correlation of outcomes within municipalities. Fitted models were used to project the impact of expanded DOT coverage, with robustness tested using alternative specifications. Results: The study included 278 007 individuals from 4783 municipalities. Average DOT coverage was 45.3%, with significant geographic variability. Treatment success was 86.9% with DOT and 73.2% without DOT. DOT coverage was associated with a 1.46 (95% confidence interval: 1.38, 1.55) odds ratio (OR) of treatment success. ORs ranged from 1.11 to 2.52 under alternative specifications, consistently indicating a positive impact. Scenario analyses indicated that reducing DOT nonutilization in each municipality by 50% would reduce the proportion of unsuccessful treatment outcomes by 7.1% (6.1, 8.2), equivalent to an average 5.5 (4.7, 6.3) percentage point increase in success probability for individuals newly receiving DOT. Conclusions: In this routine programmatic setting, higher DOT utilization was associated with better treatment outcomes, underscoring the importance of adherence-supported interventions for TB care.
- 1 July 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (7)
Open AccessThe Impact of Directly Observed Therapy on Successful Tuberculosis Treatment: A Statistical Analysis of National Notifications Data
Background: Directly Observed Therapy (DOT) is a recommended modality for tuberculosis (TB) treatment, yet is underutilized in many settings. Although DOT has been evaluated in clinical trials, less is known about its effectiveness in routine programs. We estimated the contribution of DOT to TB treatment success in Brazil. Methods: Using data from Brazil's National Disease Notification System for 2015–2018, we fit regression models estimating the relationship between DOT coverage and individual treatment success, leveraging municipality-level variation in DOT usage to avoid confounding due to nonrandom DOT receipt at the individual level. Models were adjusted for demographic and clinical covariates, using generalized estimating equations to account for correlation of outcomes within municipalities. Fitted models were used to project the impact of expanded DOT coverage, with robustness tested using alternative specifications. Results: The study included 278 007 individuals from 4783 municipalities. Average DOT coverage was 45.3%, with significant geographic variability. Treatment success was 86.9% with DOT and 73.2% without DOT. DOT coverage was associated with a 1.46 (95% confidence interval: 1.38, 1.55) odds ratio (OR) of treatment success. ORs ranged from 1.11 to 2.52 under alternative specifications, consistently indicating a positive impact. Scenario analyses indicated that reducing DOT nonutilization in each municipality by 50% would reduce the proportion of unsuccessful treatment outcomes by 7.1% (6.1, 8.2), equivalent to an average 5.5 (4.7, 6.3) percentage point increase in success probability for individuals newly receiving DOT. Conclusions: In this routine programmatic setting, higher DOT utilization was associated with better treatment outcomes, underscoring the importance of adherence-supported interventions for TB care.
- Open Access
- 22 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005114
Differences in tuberculosis prevalence by sex in low- and middle-income countries over 1993–2025: A systematic review and meta-analysis
Background: Global and national initiatives to combat tuberculosis (TB) have expanded over recent years. Despite this, the TB burden remains high in some population groups, with men recognized as having elevated TB risks. Summary measures of sex differences in TB prevalence were last estimated in 2016. Since then, many additional prevalence surveys have been conducted, including in the highest TB burden countries. We conducted a systematic review of sex-stratified TB prevalence survey data published over 1993–2025, to provide updated estimates of male-to-female (M:F) TB prevalence ratios and determine whether sex-related disparities in TB burden have closed over time. Methods and findings: We identified surveys reporting community-representative, sex-stratified estimates of pulmonary TB prevalence in low- and middle-income countries (LMICs), including surveys from an earlier review (covering January 1993–March 2016) and a new systematic review (covering 1st December 2015–13th October 2025). This review was prospectively registered with PROSPERO (CRD42024503853) and included searches of PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO. We extracted data on bacteriologically confirmed and smear-positive TB prevalence among adults (aged ≥ 15 years), stratified by sex. Risk of bias was evaluated using eight criteria specific to prevalence surveys. We fit multi-level Bayesian regression models with study- and country-level random effects to estimate the M:F ratio of TB prevalence (male prevalence divided by female prevalence), overall and for key subgroups. In meta-regression analyses, we estimated how prevalence ratios varied over time and according to known TB risk factors and TB case definitions. We identified 10,124 publications and extracted data from 100 eligible studies representing 102 unique prevalence surveys and 4,658,310 participants (45.6% male) in 33 LMICs. TB prevalence was higher in men than women in 90/102 of the included surveys, with a pooled M:F prevalence ratio of 2.02 (95% credible interval (CrI): 1.71, 2.34) for bacteriologically confirmed TB and 2.38 (95% CrI: 1.91, 2.90) for smear-positive TB. Time trend analyses showed a 2.0% (95% CrI: −0.2, 4.5%) average annual change in the M:F ratio of bacteriologically confirmed TB over the study period. The M:F prevalence ratio was estimated to be higher for countries with greater excess HIV prevalence among men, and countries with greater gender equity (as measured by the United Nation’s Gender Development Index). The estimated M:F prevalence ratio was also higher for surveys that did not restrict testing to individuals reporting TB symptoms. Study limitations include heterogeneity in survey methods and definitions, as well as limited data from the Americas, Eastern Mediterranean, and Europe WHO world regions and post-COVID-19 period. Conclusions: Men in LMICs consistently experience TB at a higher prevalence than women. Time trend estimates are uncertain, but consistent with widening sex differences in TB prevalence over the last three decades, despite efforts to address the risk factors underlying this excess TB burden.
- 22 May 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (5) , e1005114
Open AccessDifferences in tuberculosis prevalence by sex in low- and middle-income countries over 1993–2025: A systematic review and meta-analysis
Background: Global and national initiatives to combat tuberculosis (TB) have expanded over recent years. Despite this, the TB burden remains high in some population groups, with men recognized as having elevated TB risks. Summary measures of sex differences in TB prevalence were last estimated in 2016. Since then, many additional prevalence surveys have been conducted, including in the highest TB burden countries. We conducted a systematic review of sex-stratified TB prevalence survey data published over 1993–2025, to provide updated estimates of male-to-female (M:F) TB prevalence ratios and determine whether sex-related disparities in TB burden have closed over time. Methods and findings: We identified surveys reporting community-representative, sex-stratified estimates of pulmonary TB prevalence in low- and middle-income countries (LMICs), including surveys from an earlier review (covering January 1993–March 2016) and a new systematic review (covering 1st December 2015–13th October 2025). This review was prospectively registered with PROSPERO (CRD42024503853) and included searches of PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO. We extracted data on bacteriologically confirmed and smear-positive TB prevalence among adults (aged ≥ 15 years), stratified by sex. Risk of bias was evaluated using eight criteria specific to prevalence surveys. We fit multi-level Bayesian regression models with study- and country-level random effects to estimate the M:F ratio of TB prevalence (male prevalence divided by female prevalence), overall and for key subgroups. In meta-regression analyses, we estimated how prevalence ratios varied over time and according to known TB risk factors and TB case definitions. We identified 10,124 publications and extracted data from 100 eligible studies representing 102 unique prevalence surveys and 4,658,310 participants (45.6% male) in 33 LMICs. TB prevalence was higher in men than women in 90/102 of the included surveys, with a pooled M:F prevalence ratio of 2.02 (95% credible interval (CrI): 1.71, 2.34) for bacteriologically confirmed TB and 2.38 (95% CrI: 1.91, 2.90) for smear-positive TB. Time trend analyses showed a 2.0% (95% CrI: −0.2, 4.5%) average annual change in the M:F ratio of bacteriologically confirmed TB over the study period. The M:F prevalence ratio was estimated to be higher for countries with greater excess HIV prevalence among men, and countries with greater gender equity (as measured by the United Nation’s Gender Development Index). The estimated M:F prevalence ratio was also higher for surveys that did not restrict testing to individuals reporting TB symptoms. Study limitations include heterogeneity in survey methods and definitions, as well as limited data from the Americas, Eastern Mediterranean, and Europe WHO world regions and post-COVID-19 period. Conclusions: Men in LMICs consistently experience TB at a higher prevalence than women. Time trend estimates are uncertain, but consistent with widening sex differences in TB prevalence over the last three decades, despite efforts to address the risk factors underlying this excess TB burden.
- Open Access
Differences in tuberculosis prevalence among people living with and without HIV in low-and-middle-income countries: A systematic review and meta-analysis
Summary: Background: Tuberculosis (TB) and human immunodeficiency virus (HIV) are leading causes of infectious disease deaths, with disproportionate impact in low- and middle-income countries (LMICs). Despite well-established biological relationships between these diseases, there is limited information on how TB prevalence differs between people living with and without HIV. Methods: We conducted a systematic review and meta-analysis of TB prevalence surveys conducted in LMICs and published during January 1 st 1993–October 13 th 2025 (PROSPERO CRD42024503853). We extracted bacteriologically-confirmed TB prevalence estimates stratified by participant HIV status. Surveys that offered HIV testing to all, sputum-collection-eligible, or TB-positive participants were included in the primary analysis. We applied Bayesian meta-regression to estimate pooled risk ratios (RR) of bacteriologically-confirmed TB prevalence among participants living with versus without HIV. Additionally, we estimated country-level and overall TB notification-to-prevalence (N:P) ratios by HIV status. Findings: Of 10,211 potentially relevant publications, 12 TB prevalence surveys—representing 264,530 participants within nine countries in Southern and Eastern Africa—were used in the primary analysis. Reported TB prevalence was higher among participants living with versus without HIV in 11/12 surveys, with an overall pooled RR of 3·86 (95% credible interval: 2·41–5·53). N:P ratios were higher among participants living with HIV in all examined countries. The overall pooled N:P ratios were 1·74 (0·59–4·56) and 0·48 (0·17–1·20) among participants living with versus without HIV, respectively. Interpretation: In Southern and Eastern Africa, bacteriologically-confirmed TB prevalence is three- to six-times higher among people living with HIV. Comparison of prevalence and notification data suggest higher rates of TB diagnosis for people living with versus without HIV, but also indicates substantial delays in the detection of untreated TB cases for both populations. Funding: Wellcome Trust, UK National Institute for Health and Care Research, UK Foreign, Commonwealth and Development Office, NIH. Research in context: Evidence before this study: There is limited systematic evidence on how the prevalence of TB disease differs between people living with HIV and without HIV. Multiple observational cohorts have described substantially elevated TB incidence among populations with HIV, but disease prevalence will also be affected by differences in mortality and treatment uptake rates. We searched PubMed from inception through January 21, 2026 using the search string ((HIV AND TB) OR HIV/TB) AND (prevalence AND (systematic review OR meta-analysis)) without any restrictions on language. We also reviewed investigators’ personal libraries. This search yielded 506 publications; however few of these included prevalence data. An analysis conducted in 2020 synthesized HIV status-stratified data from seven national TB prevalence surveys in Africa and found that HIV prevalence was lower among prevalent TB cases than among notified cases. This study did not include subnational surveys and did not distinguish between survey participants with self-reported or test-confirmed HIV status. Added value of this study: This study synthesized TB prevalence data, stratified by participant HIV status, from national and subnational surveys conducted in LMICs and published between January 1 st 1993 and October 13 th , 2025. Collated data represented 681,402 survey participants across ten countries. All but one study were conducted in Southern and Eastern Africa. We limited our primary analysis to surveys that systematically tested participants for HIV and bacteriologically-confirmed TB. The prevalence of bacteriologically-confirmed TB was estimated to be three to six times higher than among people living with versus without HIV. Ratios of TB notifications to TB prevalence were higher for people living with HIV compared to people without HIV, suggesting higher rates of TB case detection (and likely shorter duration of disease) for people living with HIV and untreated TB than those without HIV. Implications of all available evidence: Few estimates of community-representative TB prevalence stratified by participant HIV status exist. These surveys have been concentrated in Southern and Eastern Africa, despite TB-HIV burden being distributed globally. Our findings highlight the elevated burden of TB among people living with HIV in these settings, as well as the limited data on the intersection of TB and HIV epidemiology in other world regions. Furthermore, our comparison of notification and prevalence data demonstrate substantial shortfalls in TB case detection, regardless of an individuals’ HIV status.
Open AccessDifferences in tuberculosis prevalence among people living with and without HIV in low-and-middle-income countries: A systematic review and meta-analysis
Summary: Background: Tuberculosis (TB) and human immunodeficiency virus (HIV) are leading causes of infectious disease deaths, with disproportionate impact in low- and middle-income countries (LMICs). Despite well-established biological relationships between these diseases, there is limited information on how TB prevalence differs between people living with and without HIV. Methods: We conducted a systematic review and meta-analysis of TB prevalence surveys conducted in LMICs and published during January 1 st 1993–October 13 th 2025 (PROSPERO CRD42024503853). We extracted bacteriologically-confirmed TB prevalence estimates stratified by participant HIV status. Surveys that offered HIV testing to all, sputum-collection-eligible, or TB-positive participants were included in the primary analysis. We applied Bayesian meta-regression to estimate pooled risk ratios (RR) of bacteriologically-confirmed TB prevalence among participants living with versus without HIV. Additionally, we estimated country-level and overall TB notification-to-prevalence (N:P) ratios by HIV status. Findings: Of 10,211 potentially relevant publications, 12 TB prevalence surveys—representing 264,530 participants within nine countries in Southern and Eastern Africa—were used in the primary analysis. Reported TB prevalence was higher among participants living with versus without HIV in 11/12 surveys, with an overall pooled RR of 3·86 (95% credible interval: 2·41–5·53). N:P ratios were higher among participants living with HIV in all examined countries. The overall pooled N:P ratios were 1·74 (0·59–4·56) and 0·48 (0·17–1·20) among participants living with versus without HIV, respectively. Interpretation: In Southern and Eastern Africa, bacteriologically-confirmed TB prevalence is three- to six-times higher among people living with HIV. Comparison of prevalence and notification data suggest higher rates of TB diagnosis for people living with versus without HIV, but also indicates substantial delays in the detection of untreated TB cases for both populations. Funding: Wellcome Trust, UK National Institute for Health and Care Research, UK Foreign, Commonwealth and Development Office, NIH. Research in context: Evidence before this study: There is limited systematic evidence on how the prevalence of TB disease differs between people living with HIV and without HIV. Multiple observational cohorts have described substantially elevated TB incidence among populations with HIV, but disease prevalence will also be affected by differences in mortality and treatment uptake rates. We searched PubMed from inception through January 21, 2026 using the search string ((HIV AND TB) OR HIV/TB) AND (prevalence AND (systematic review OR meta-analysis)) without any restrictions on language. We also reviewed investigators’ personal libraries. This search yielded 506 publications; however few of these included prevalence data. An analysis conducted in 2020 synthesized HIV status-stratified data from seven national TB prevalence surveys in Africa and found that HIV prevalence was lower among prevalent TB cases than among notified cases. This study did not include subnational surveys and did not distinguish between survey participants with self-reported or test-confirmed HIV status. Added value of this study: This study synthesized TB prevalence data, stratified by participant HIV status, from national and subnational surveys conducted in LMICs and published between January 1 st 1993 and October 13 th , 2025. Collated data represented 681,402 survey participants across ten countries. All but one study were conducted in Southern and Eastern Africa. We limited our primary analysis to surveys that systematically tested participants for HIV and bacteriologically-confirmed TB. The prevalence of bacteriologically-confirmed TB was estimated to be three to six times higher than among people living with versus without HIV. Ratios of TB notifications to TB prevalence were higher for people living with HIV compared to people without HIV, suggesting higher rates of TB case detection (and likely shorter duration of disease) for people living with HIV and untreated TB than those without HIV. Implications of all available evidence: Few estimates of community-representative TB prevalence stratified by participant HIV status exist. These surveys have been concentrated in Southern and Eastern Africa, despite TB-HIV burden being distributed globally. Our findings highlight the elevated burden of TB among people living with HIV in these settings, as well as the limited data on the intersection of TB and HIV epidemiology in other world regions. Furthermore, our comparison of notification and prevalence data demonstrate substantial shortfalls in TB case detection, regardless of an individuals’ HIV status.
- Open Access
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1004779
Urban and rural prevalence of tuberculosis in low- and middle-income countries: A systematic review and meta-analysis
Background: Urban and rural settings differ in key determinants of tuberculosis (TB) burden, including transmission dynamics, social and structural determinants, and healthcare access. However, understanding of urban and rural TB burden is limited, hindering implementation of public health interventions to end TB. Methods and findings: We conducted a systematic review and meta-analysis of urban and rural differences in adult pulmonary TB prevalence in low- and middle-income countries. We searched PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO for community-representative prevalence surveys conducted between 1st January 1993 and 14th October 2025. Studies focussing solely on symptomatic or healthcare-seeking individuals and those conducted in congregate settings like prisons, universities, and health facilities were excluded. Risk of bias was assessed using a tool for prevalence surveys. Bayesian multilevel meta-regression was used to estimate pooled urban-to-rural prevalence ratios (PR) for bacteriologically-confirmed and smear-positive TB overall, and by World Health Organization (WHO) region. We also investigated time trends in the urban-to-rural prevalence ratio, and associations between urban-to-rural prevalence ratios and survey-level risk of bias (not low versus low), TB screening algorithm (whether used symptom screening for sputum eligibility), national TB incidence, percentage of population living in urban areas, and representativeness of prevalence surveys (national versus sub-national). To estimate the number of people with prevalent TB in urban and rural areas in study countries, and how these have changed between 2000 and 2024, we fitted a Bayesian multivariate model to WHO incidence and case detection ratio data and combined these estimates with assumptions about the duration of treated and untreated TB and the distribution of urban and rural populations. We included 47 surveys conducted between 2000 and 2024, encompassing 2,454,443 participants. The pooled urban-to-rural PR of bacteriologically-confirmed TB was 1.09 (95% credible interval [CrI]: 0.90, 1.30) and was 1.24 (95% CrI: 0.94, 1.61) for smear-positive TB. However, there were substantial differences between WHO regions: averaged across the 24 year study period the African Region had higher urban bacteriologically-confirmed prevalence (PR 1.18, 95% CrI: 0.91, 1.52), while the Western Pacific Region (PR 0.85, 95% CrI: 0.64, 1.07) and South-East Asia Region (PR 0.86, 95% CrI: 0.67, 1.08) had broadly similar urban and rural prevalence. Time trends indicated an increase in the overall bacteriologically-confirmed urban-to-rural prevalence ratio between 2000 and 2024, with a mean PR increase of 2.4% (95% CrI: −0.8%, 6.0%) per year. We estimated that, for 2024 in the 26 represented study countries (combined population: 2.24 billion [48.3%] urban; 2.40 billion [51.7%] rural), 49% (6.6 million, 95% CrI: 4.2, 12.0 million) of prevalent TB was in urban areas, and 51% (6.8 million, 95% CrI: 4.2, 12.0 million) in rural areas. Within countries, there were striking changes in the urban and rural distribution between 2000 and 2024, with the share of urban cases increasing in nearly all countries. The main limitations include lack of unified definitions for urban and rural areas, and absence of data for some global regions (e.g., Americas and Europe). Conclusion: Between 2000 and 2024, TB epidemics have become increasingly urbanised, both in proportional and absolute terms, although with considerable variation in timing across countries and regions. Public health approaches tailored to urban and rural TB epidemiology and demography will be required to end TB.
- 6 April 2026
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 23 (4) , e1004779
Open AccessUrban and rural prevalence of tuberculosis in low- and middle-income countries: A systematic review and meta-analysis
Background: Urban and rural settings differ in key determinants of tuberculosis (TB) burden, including transmission dynamics, social and structural determinants, and healthcare access. However, understanding of urban and rural TB burden is limited, hindering implementation of public health interventions to end TB. Methods and findings: We conducted a systematic review and meta-analysis of urban and rural differences in adult pulmonary TB prevalence in low- and middle-income countries. We searched PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO for community-representative prevalence surveys conducted between 1st January 1993 and 14th October 2025. Studies focussing solely on symptomatic or healthcare-seeking individuals and those conducted in congregate settings like prisons, universities, and health facilities were excluded. Risk of bias was assessed using a tool for prevalence surveys. Bayesian multilevel meta-regression was used to estimate pooled urban-to-rural prevalence ratios (PR) for bacteriologically-confirmed and smear-positive TB overall, and by World Health Organization (WHO) region. We also investigated time trends in the urban-to-rural prevalence ratio, and associations between urban-to-rural prevalence ratios and survey-level risk of bias (not low versus low), TB screening algorithm (whether used symptom screening for sputum eligibility), national TB incidence, percentage of population living in urban areas, and representativeness of prevalence surveys (national versus sub-national). To estimate the number of people with prevalent TB in urban and rural areas in study countries, and how these have changed between 2000 and 2024, we fitted a Bayesian multivariate model to WHO incidence and case detection ratio data and combined these estimates with assumptions about the duration of treated and untreated TB and the distribution of urban and rural populations. We included 47 surveys conducted between 2000 and 2024, encompassing 2,454,443 participants. The pooled urban-to-rural PR of bacteriologically-confirmed TB was 1.09 (95% credible interval [CrI]: 0.90, 1.30) and was 1.24 (95% CrI: 0.94, 1.61) for smear-positive TB. However, there were substantial differences between WHO regions: averaged across the 24 year study period the African Region had higher urban bacteriologically-confirmed prevalence (PR 1.18, 95% CrI: 0.91, 1.52), while the Western Pacific Region (PR 0.85, 95% CrI: 0.64, 1.07) and South-East Asia Region (PR 0.86, 95% CrI: 0.67, 1.08) had broadly similar urban and rural prevalence. Time trends indicated an increase in the overall bacteriologically-confirmed urban-to-rural prevalence ratio between 2000 and 2024, with a mean PR increase of 2.4% (95% CrI: −0.8%, 6.0%) per year. We estimated that, for 2024 in the 26 represented study countries (combined population: 2.24 billion [48.3%] urban; 2.40 billion [51.7%] rural), 49% (6.6 million, 95% CrI: 4.2, 12.0 million) of prevalent TB was in urban areas, and 51% (6.8 million, 95% CrI: 4.2, 12.0 million) in rural areas. Within countries, there were striking changes in the urban and rural distribution between 2000 and 2024, with the share of urban cases increasing in nearly all countries. The main limitations include lack of unified definitions for urban and rural areas, and absence of data for some global regions (e.g., Americas and Europe). Conclusion: Between 2000 and 2024, TB epidemics have become increasingly urbanised, both in proportional and absolute terms, although with considerable variation in timing across countries and regions. Public health approaches tailored to urban and rural TB epidemiology and demography will be required to end TB.
- Open Access
- 5 December 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (12) , e018822
Systematic differences in TB treatment outcomes across Brazil by patient- and area-related factors: an analysis of national disease registry data
Background: Many individuals initiating tuberculosis (TB) treatment do not successfully complete the regimen. Understanding variation in treatment outcomes could reveal opportunities to improve the effectiveness of TB treatment services. Methods: We extracted data on treatment outcomes and patient covariates from Brazil’s National Disease Notification Information System, for new TB patients diagnosed during 2015–2018. We analysed whether or not patients experienced an unsuccessful treatment outcome (any death on treatment, loss to follow-up or treatment failure). We constructed a statistical model (logistic regression with regularised two-way interactions) to predict treatment outcomes as a function of socio-demographic factors, co-prevalent health conditions, health behaviours, membership of vulnerable populations and form of TB disease. We used this model to decompose state- and municipality-level variation in treatment outcomes into differences attributable to patient-level and area-level factors. Results: Treatment outcomes data for 259 449 individuals were used for the analysis. Across Brazilian states, variation in unsuccessful treatment due to patient-level factors was substantially less than variation due to area-level factors, with the difference between best and worst performing states (lowest and highest fraction with unsuccessful treatment, respectively) equal to 7.1 and 13.3 percentage points for patient-level and area-level factors. Similar results were estimated at the municipality level, with 9.3 percentage points separating best and worst performing municipalities according to patient-level factors, and 20.5 percentage points separating best and worst performing municipalities to area-level factors. Results were similar when we analysed loss to follow-up as an outcome. Conclusions: Our analysis revealed substantial variation in TB treatment outcomes across states and municipalities, with only a minority attributable to patient-level factors. Area-level variation likely reflects consequences of differences in health system organisation or socio-environmental factors not reflected in patient-level data. Further research on these factors is needed to identify effective approaches to TB care, reduce geographic disparities and improve treatment outcome.
- 5 December 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (12) , e018822
Open AccessSystematic differences in TB treatment outcomes across Brazil by patient- and area-related factors: an analysis of national disease registry data
Background: Many individuals initiating tuberculosis (TB) treatment do not successfully complete the regimen. Understanding variation in treatment outcomes could reveal opportunities to improve the effectiveness of TB treatment services. Methods: We extracted data on treatment outcomes and patient covariates from Brazil’s National Disease Notification Information System, for new TB patients diagnosed during 2015–2018. We analysed whether or not patients experienced an unsuccessful treatment outcome (any death on treatment, loss to follow-up or treatment failure). We constructed a statistical model (logistic regression with regularised two-way interactions) to predict treatment outcomes as a function of socio-demographic factors, co-prevalent health conditions, health behaviours, membership of vulnerable populations and form of TB disease. We used this model to decompose state- and municipality-level variation in treatment outcomes into differences attributable to patient-level and area-level factors. Results: Treatment outcomes data for 259 449 individuals were used for the analysis. Across Brazilian states, variation in unsuccessful treatment due to patient-level factors was substantially less than variation due to area-level factors, with the difference between best and worst performing states (lowest and highest fraction with unsuccessful treatment, respectively) equal to 7.1 and 13.3 percentage points for patient-level and area-level factors. Similar results were estimated at the municipality level, with 9.3 percentage points separating best and worst performing municipalities according to patient-level factors, and 20.5 percentage points separating best and worst performing municipalities to area-level factors. Results were similar when we analysed loss to follow-up as an outcome. Conclusions: Our analysis revealed substantial variation in TB treatment outcomes across states and municipalities, with only a minority attributable to patient-level factors. Area-level variation likely reflects consequences of differences in health system organisation or socio-environmental factors not reflected in patient-level data. Further research on these factors is needed to identify effective approaches to TB care, reduce geographic disparities and improve treatment outcome.
- Open Access
- 1 May 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (3) , 444-451
Preliminary evaluation of the effect of revised reimbursement scheme in outpatient hemodialysis for medical aid recipients in Korea
Background: South Korea has universal health coverage guaranteeing equitable healthcare for all. However, equity issues have been raised regarding hemodialysis reimbursement for medical aid recipients with chronic kidney disease. Physicians and civic groups demanded a revision of the discriminatory policy, and in response, the Ministry of Health and Welfare amended the hemodialysis case payment scheme. This study aims to evaluate the effectiveness of the reform and detect any unintended policy outcomes. Methods: Data from the Health Insurance Review and Assessment Service of Korea was used. All subjects were patients with chronic kidney disease who received outpatient hemodialysis and medical aid from April 2017 to March 2022. The dzata was analyzed with descriptive statistics, and the generalized estimation equation was used to control for covariates and identify policy effects. Results: The reform of the case payment scheme in 2021 raised the compensation level per hemodialysis case, which was fixed for 7 years from 2014, by approximately 2,000 Korean won. There was no negative effect such as additional expenditure resulting from an unintentional increase in medical use. Conclusion: A year has passed since the implementation of the outpatient hemodialysis rate system reform for medical aid recipients. Our results indicate that the reform has gone smoothly, and we anticipate continuous efforts by the government to guarantee universal health coverage to medical aid recipients. Through such consistent endeavors to correct the discriminatory aspects of policies, South Korea will achieve true universal health coverage.
- 1 May 2025
- Published by The Korean Society of Nephrology in Kidney Research and Clinical Practice
- Vol. 44 (3) , 444-451
Open AccessPreliminary evaluation of the effect of revised reimbursement scheme in outpatient hemodialysis for medical aid recipients in Korea
Background: South Korea has universal health coverage guaranteeing equitable healthcare for all. However, equity issues have been raised regarding hemodialysis reimbursement for medical aid recipients with chronic kidney disease. Physicians and civic groups demanded a revision of the discriminatory policy, and in response, the Ministry of Health and Welfare amended the hemodialysis case payment scheme. This study aims to evaluate the effectiveness of the reform and detect any unintended policy outcomes. Methods: Data from the Health Insurance Review and Assessment Service of Korea was used. All subjects were patients with chronic kidney disease who received outpatient hemodialysis and medical aid from April 2017 to March 2022. The dzata was analyzed with descriptive statistics, and the generalized estimation equation was used to control for covariates and identify policy effects. Results: The reform of the case payment scheme in 2021 raised the compensation level per hemodialysis case, which was fixed for 7 years from 2014, by approximately 2,000 Korean won. There was no negative effect such as additional expenditure resulting from an unintentional increase in medical use. Conclusion: A year has passed since the implementation of the outpatient hemodialysis rate system reform for medical aid recipients. Our results indicate that the reform has gone smoothly, and we anticipate continuous efforts by the government to guarantee universal health coverage to medical aid recipients. Through such consistent endeavors to correct the discriminatory aspects of policies, South Korea will achieve true universal health coverage.
- Open Access
Systematic differences in TB treatment outcomes across in Brazil by patient- and area-related factors: an analysis of national disease registry data
Background: A substantial fraction of individuals initiating tuberculosis (TB) treatment do not successfully complete the regimen. Understanding variation in TB treatment outcomes could reveal opportunities to improve the effectiveness of TB treatment services. Methods: We extracted data on TB treatment outcomes, patient covariates, and location of residence from Brazil’s National Disease Notification Information System, for all new TB patients diagnosed during 2015-2018. We analyzed whether or not patients experienced an unsuccessful treatment outcome (any death on treatment, loss to follow-up, or treatment failure). We constructed a statistical model predicting treatment outcome as a function of patient-level covariates, including socio-demographic factors, co-prevalent health conditions, health behaviors, membership of vulnerable populations, and diagnosed form of TB disease. We used this model to decompose state- and municipality-level variation in treatment outcomes into differences attributable to patient-level factors and area-level factors, respectively. Results: Treatment outcomes data for 259,449 individuals were used for the analysis. Across Brazilian states, variation in unsuccessful treatment due to patient-level factors was substantially less that variation due to area-level factors, with the difference between best and worst performing states 7.1 and 13.3 percentage points for patient-level and area-level factors, respectively. Similar results were estimated at the municipality-level, with 9.3 percentage points separating best and worst performing municipalities according to patient-level factors, and 20.5 percentage points separating best and worst performing municipalities according to area-level factors. Results were similar when we analyzed loss to follow-up as an outcome. Conclusions: The results of this analysis revealed substantial variation in TB treatment outcomes across states and municipalities in Brazil, which could not be explained by differences in patient-level factors. This area-level variation likely reflects the consequences of differences in health system organization, clinical practices, and other socio-environmental factors not reflected in patient-level data. Further research to reveal the reasons for these differences is urgently needed to identify effective approaches to TB care, reduce geographic disparities in treatment effectiveness across Brazil, and increase the fraction of patients who successfully complete TB treatment.
Open AccessSystematic differences in TB treatment outcomes across in Brazil by patient- and area-related factors: an analysis of national disease registry data
Background: A substantial fraction of individuals initiating tuberculosis (TB) treatment do not successfully complete the regimen. Understanding variation in TB treatment outcomes could reveal opportunities to improve the effectiveness of TB treatment services. Methods: We extracted data on TB treatment outcomes, patient covariates, and location of residence from Brazil’s National Disease Notification Information System, for all new TB patients diagnosed during 2015-2018. We analyzed whether or not patients experienced an unsuccessful treatment outcome (any death on treatment, loss to follow-up, or treatment failure). We constructed a statistical model predicting treatment outcome as a function of patient-level covariates, including socio-demographic factors, co-prevalent health conditions, health behaviors, membership of vulnerable populations, and diagnosed form of TB disease. We used this model to decompose state- and municipality-level variation in treatment outcomes into differences attributable to patient-level factors and area-level factors, respectively. Results: Treatment outcomes data for 259,449 individuals were used for the analysis. Across Brazilian states, variation in unsuccessful treatment due to patient-level factors was substantially less that variation due to area-level factors, with the difference between best and worst performing states 7.1 and 13.3 percentage points for patient-level and area-level factors, respectively. Similar results were estimated at the municipality-level, with 9.3 percentage points separating best and worst performing municipalities according to patient-level factors, and 20.5 percentage points separating best and worst performing municipalities according to area-level factors. Results were similar when we analyzed loss to follow-up as an outcome. Conclusions: The results of this analysis revealed substantial variation in TB treatment outcomes across states and municipalities in Brazil, which could not be explained by differences in patient-level factors. This area-level variation likely reflects the consequences of differences in health system organization, clinical practices, and other socio-environmental factors not reflected in patient-level data. Further research to reveal the reasons for these differences is urgently needed to identify effective approaches to TB care, reduce geographic disparities in treatment effectiveness across Brazil, and increase the fraction of patients who successfully complete TB treatment.
- Open Access
Predictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Introduction Tuberculosis (TB) causes over 1 million deaths annually. Providing effective treatment is a key strategy for reducing TB deaths. In this study, we identified factors associated with unsuccessful treatment outcomes among individuals treated for TB in Brazil. Methods We obtained data on individuals treated for TB between 2015 and 2018 from Brazil’s National Disease Notification System (SINAN). We excluded patients with a history of prior TB disease or with diagnosed TB drug resistance. We extracted information on patient-level factors potentially associated with successful treatment, including demographic and social factors, comorbid health conditions, health-related behaviors, health system level at which care was provided, use of directly observed therapy (DOT), and clinical examination results. We categorized treatment outcomes as successful (cure, completed) or unsuccessful (death, regimen failure, loss to follow-up). We fit multivariate logistic regression models to identify factors associated with unsuccessful treatment outcome. Results Among 259,484 individuals treated for drug susceptible TB, 19.7% experienced an unsuccessful treatment outcome (death during treatment 7.8%, regimen failure 0.1%, loss to follow-up 11.9%). The odds of unsuccessful outcome were higher with older age (adjusted odds ratio (aOR) 2.90 [95% confidence interval: 2.62–3.21] for 85-100-year-olds vs. 25-34-year-olds), male sex (aOR 1.28 [1.25– 1.32], vs. female sex), Black race (aOR 1.23 [1.19–1.28], vs. White race), no education (aOR 2.03 [1.91– 2.17], vs. complete high school education), HIV infection (aOR 2.72 [2.63–2.81], vs. no HIV infection), illicit drug use (aOR 1.95 [1.88–2.01], vs. no illicit drug use), alcohol consumption (aOR 1.46 [1.41– 1.50], vs. no alcohol consumption), smoking (aOR 1.20 [1.16–1.23], vs. non-smoking), homelessness (aOR 3.12 [2.95–3.31], vs. no homelessness), and immigrant status (aOR 1.27 [1.11–1.45], vs. non-immigrants). Treatment was more likely to be unsuccessful for individuals treated in tertiary care (aOR 2.20 [2.14–2.27], vs. primary care), and for patients not receiving DOT (aOR 2.35 [2.29–2.41], vs. receiving DOT). Conclusion The risk of unsuccessful TB treatment varied systematically according to individual and service-related factors. Concentrating clinical attention on individuals with a high risk of poor treatment outcomes could improve the overall effectiveness of TB treatment in Brazil.
Open AccessPredictors of unsuccessful tuberculosis treatment outcomes in Brazil: an analysis of 259,484 patient records
Introduction Tuberculosis (TB) causes over 1 million deaths annually. Providing effective treatment is a key strategy for reducing TB deaths. In this study, we identified factors associated with unsuccessful treatment outcomes among individuals treated for TB in Brazil. Methods We obtained data on individuals treated for TB between 2015 and 2018 from Brazil’s National Disease Notification System (SINAN). We excluded patients with a history of prior TB disease or with diagnosed TB drug resistance. We extracted information on patient-level factors potentially associated with successful treatment, including demographic and social factors, comorbid health conditions, health-related behaviors, health system level at which care was provided, use of directly observed therapy (DOT), and clinical examination results. We categorized treatment outcomes as successful (cure, completed) or unsuccessful (death, regimen failure, loss to follow-up). We fit multivariate logistic regression models to identify factors associated with unsuccessful treatment outcome. Results Among 259,484 individuals treated for drug susceptible TB, 19.7% experienced an unsuccessful treatment outcome (death during treatment 7.8%, regimen failure 0.1%, loss to follow-up 11.9%). The odds of unsuccessful outcome were higher with older age (adjusted odds ratio (aOR) 2.90 [95% confidence interval: 2.62–3.21] for 85-100-year-olds vs. 25-34-year-olds), male sex (aOR 1.28 [1.25– 1.32], vs. female sex), Black race (aOR 1.23 [1.19–1.28], vs. White race), no education (aOR 2.03 [1.91– 2.17], vs. complete high school education), HIV infection (aOR 2.72 [2.63–2.81], vs. no HIV infection), illicit drug use (aOR 1.95 [1.88–2.01], vs. no illicit drug use), alcohol consumption (aOR 1.46 [1.41– 1.50], vs. no alcohol consumption), smoking (aOR 1.20 [1.16–1.23], vs. non-smoking), homelessness (aOR 3.12 [2.95–3.31], vs. no homelessness), and immigrant status (aOR 1.27 [1.11–1.45], vs. non-immigrants). Treatment was more likely to be unsuccessful for individuals treated in tertiary care (aOR 2.20 [2.14–2.27], vs. primary care), and for patients not receiving DOT (aOR 2.35 [2.29–2.41], vs. receiving DOT). Conclusion The risk of unsuccessful TB treatment varied systematically according to individual and service-related factors. Concentrating clinical attention on individuals with a high risk of poor treatment outcomes could improve the overall effectiveness of TB treatment in Brazil.